

# Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform - Pipeline Review, H2 2019

<https://marketpublishers.com/r/P723A2937CCAEN.html>

Date: December 2019

Pages: 127

Price: US\$ 3,500.00 (Single User License)

ID: P723A2937CCAEN

## Abstracts

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform - Pipeline Review, H2 2019

### SUMMARY

According to the recently published report 'Phosphatidylinositol 4,5 Bisphosphate 3 - Pipeline Review, H2 2019'; Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) pipeline Target constitutes close to 21 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes.

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit gamma isoform is an enzyme encoded by the PIK3CG gene. It plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. It is involved in immune, inflammatory and allergic responses. It modulates leukocyte chemotaxis to inflammatory sites and in response to chemoattractant agents. It regulates T-lymphocyte proliferation and cytokine production.

The report 'Phosphatidylinositol 4,5 Bisphosphate 3 - Pipeline Review, H2 2019' outlays comprehensive information on the Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 13 and 2 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Respiratory, Immunology, Hematological Disorders, Infectious Disease and Undisclosed which include indications Cutaneous T-Cell Lymphoma, Solid Tumor, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Ovarian Cancer, Peripheral T-Cell Lymphomas (PTCL), Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Asthma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Head And Neck Cancer Squamous Cell Carcinoma, Lung Cancer, Lymphoma, Multiple Myeloma (Kahler Disease), Pancreatic Cancer, Renal Cell Carcinoma, T-Cell Lymphomas, Triple-Negative Breast Cancer (TNBC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Allergic Asthma, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Bladder Cancer, Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Cystic Fibrosis, Gallbladder Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Human Immunodeficiency Virus (HIV) Infections (AIDS), Idiopathic Pulmonary Fibrosis, Inflammation, Malignant Mesothelioma, Marginal Zone B-cell Lymphoma, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Natural Killer Cell Lymphomas, Neuroblastoma, Neutrophilia, Non-Small Cell Lung Cancer, Primary CNS Lymphoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Rheumatoid Arthritis, T-

Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia),  
Unspecified and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153)

The report reviews Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics and enlists all their major and minor projects

The report assesses Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics based on

mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma

Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Overview

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) -

Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) -

Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Companies

Involved in Therapeutics Development

Applied Therapeutics Inc

Arcus Biosciences Inc

AstraZeneca Plc

BioMed Valley Discoveries Inc

Chia Tai Tianqing Pharmaceutical Group Co Ltd.

Hutchison MediPharma Ltd

Infinity Pharmaceuticals Inc

Kither Biotech Srl

Novartis AG

PIQUR Therapeutics AG

Rhizen Pharmaceuticals SA

Sichuan Sinovation Bio-technology Co Ltd

SignalRx Pharmaceuticals Inc

Sphaera Pharma Pte Ltd

Verastem Inc

Vertex Pharmaceuticals Inc

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform  
(Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or  
Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein  
Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Drug  
Profiles

AB-610 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-8154 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bimiralisib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BVD-723 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CL-27 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

duvelisib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IPI-549 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KIT-2014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PQR-514 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF-2523 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PI3K Delta and PI3K Gamma for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PI3K Gamma for Unspecified Indication - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PIK3CG for Chronic Obstructive Pulmonary Disease and Neutrophilia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Pan PI3K for Ovarian Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PIK3CA and PIK3CG for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action



R&D Progress

Small Molecules to Inhibit PIK3CD and PIK3CG for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SN-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SPR-965 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tenalisib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WX-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Dormant Products

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Discontinued Products

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Product Development Milestones

Featured News & Press Releases

Dec 07, 2019: Verastem oncology presents phase 2 PRIMO study data evaluating duvelisib in relapsed or refractory peripheral T-Cell lymphoma at the american society of

hematology 2019 annual meeting

Nov 25, 2019: Verastem Oncology announces submission of a marketing authorization application to the European Medicines Agency for COPIKTRA (duvelisib)

Nov 06, 2019: Verastem Oncology to phase 2 PRIMO study data evaluating duvelisib in relapsed or refractory peripheral t-cell lymphoma at the American Society of Hematology 2019 Annual Meeting

Oct 23, 2019: Verastem Oncology announces COPIKTRA (Duvelisib) presentations at the Lymphoma & Myeloma 2019 International Congress

Oct 07, 2019: Verastem Oncology announces dosing of first patient in Vakult Honsha Japanese bridging study evaluating Copiktra (Duvelisib) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Oct 03, 2019: Verastem Oncology receives Orphan Drug Designation from FDA for COPIKTRA for the treatment of T-Cell Lymphoma

Oct 03, 2019: Verastem Oncology presents new preclinical Duvelisib data at the 5th International Conference on new concepts in lymphoid malignancies

Sep 25, 2019: AstraZeneca to present AZD8154 data at ERS International Congress

Sep 20, 2019: Verastem Oncology announces COPIKTRA (Duvelisib) presentations at the 18th Annual International Workshop on Chronic Lymphocytic Leukemia

Sep 04, 2019: Infinity Pharmaceuticals announces the initiation of two clinical trials evaluating IPI-549 in novel Triple Combination Therapies for the treatment of Solid Tumors

Sep 03, 2019: Verastem Oncology announces COPIKTRA (Duvelisib) presentations at the Society of Hematologic Oncology 2019 Annual Meeting

Aug 22, 2019: Infinity Pharmaceuticals announces transition of Samuel Agresta, M.D., from chief medical officer to board of directors

Jun 21, 2019: Verastem Oncology presents COPIKTRA (Duvelisib) data in peripheral T-cell lymphoma at the 2019 International Conference on Malignant Lymphoma

Jun 17, 2019: Verastem Oncology presents COPIKTRA (Duvelisib) data at the European Hematology Association 2019 Annual Meeting

May 15, 2019: Verastem Oncology to present new COPIKTRA (Duvelisib) dose modification data from patients treated in the phase 3 DUO study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Indications, H2 2019  
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019  
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019  
Number of Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019 (Contd..1), H2 2019  
Products under Development by Companies, H2 2019 (Contd..2), H2 2019  
Products under Development by Companies, H2 2019 (Contd..3), H2 2019  
Products under Development by Companies, H2 2019 (Contd..4), H2 2019  
Number of Products under Investigation by Universities/Institutes, H2 2019  
Products under Investigation by Universities/Institutes, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Pipeline by Applied Therapeutics Inc, H2 2019  
Pipeline by Arcus Biosciences Inc, H2 2019  
Pipeline by AstraZeneca Plc, H2 2019  
Pipeline by BioMed Valley Discoveries Inc, H2 2019  
Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd., H2 2019  
Pipeline by Hutchison MediPharma Ltd, H2 2019  
Pipeline by Infinity Pharmaceuticals Inc, H2 2019  
Pipeline by Kither Biotech Srl, H2 2019  
Pipeline by Novartis AG, H2 2019  
Pipeline by PIQUR Therapeutics AG, H2 2019  
Pipeline by Rhizen Pharmaceuticals SA, H2 2019  
Pipeline by Sichuan Sinovation Bio-technology Co Ltd, H2 2019  
Pipeline by SignalRx Pharmaceuticals Inc, H2 2019  
Pipeline by Sphaera Pharma Pte Ltd, H2 2019  
Pipeline by Verastem Inc, H2 2019  
Pipeline by Vertex Pharmaceuticals Inc, H2 2019  
Dormant Products, H2 2019  
Dormant Products, H2 2019 (Contd..1), H2 2019  
Discontinued Products, H2 2019



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Top 10 Indications, H2 2019  
Number of Products by Mechanism of Actions, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Routes of Administration, H2 2019  
Number of Products by Stage and Routes of Administration, H2 2019  
Number of Products by Molecule Types, H2 2019  
Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

Applied Therapeutics Inc  
Arcus Biosciences Inc  
AstraZeneca Plc  
BioMed Valley Discoveries Inc  
Chia Tai Tianqing Pharmaceutical Group Co Ltd.  
Hutchison MediPharma Ltd  
Infinity Pharmaceuticals Inc  
Kither Biotech Srl  
Novartis AG  
PIQUR Therapeutics AG  
Rhizen Pharmaceuticals SA  
Sichuan Sinovation Bio-technology Co Ltd  
SignalRx Pharmaceuticals Inc  
Sphaera Pharma Pte Ltd  
Verastem Inc  
Vertex Pharmaceuticals Inc

## I would like to order

Product name: Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/P723A2937CCAEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P723A2937CCAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

